Invion Ltd. (OTC:IVIXF) Filings

Invion Ltd.

Filings

FilingDateTypeFiled with
Invion Receives $0.5m R&D Tax Incentive RebateNov 18, 2026ResultsASX
Change of Director's Interest Notice - Thian ChewNov 17, 2026Ownership change noticeASX
Notification of cessation of securities - IVXNov 17, 2026FinancingASX
IVX Director Appointment/Resignation & New Company SecretaryNov 10, 2026Management or board changeASX
Appendix 4C and Quarterly Activities Report - September 2026Oct 28, 2026Quarterly reportASX
Notice of Annual General Meeting/Proxy FormOct 23, 2026Meeting noticeASX
Proposed issue of securities - IVXOct 20, 2026FinancingASX
Funding Agreements Cover Up to 85% of Clinical Trials CostsOct 20, 2026FinancingASX
Funding Agreements Cover Up to 85% of Clinical Trials CostsOct 20, 2026FinancingASX
Photosoft & Novel Immunotherapy Collab PartnershipOct 19, 2026Other filingsASX
PER: Percheron and Invion Explore Cancer Combination TherapyOct 19, 2026Other filingsASX
Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2Oct 18, 2026Operations updateASX
Application for quotation of securities - IVXOct 15, 2026FinancingASX
Proposed issue of securities - IVXSep 29, 2026FinancingASX
Director LoansSep 29, 2026FinancingASX
Appendix 4G and Corporate Governance StatementAug 26, 2026Annual reportASX
Appendix 4E and Annual ReportAug 26, 2026Annual reportASX
Initial Director's Interest Notice - Paul FIeldAug 20, 2026Ownership change noticeASX
Final Director's Interest Notice - Alistair BennallackAug 20, 2026Ownership change noticeASX
IVX Credentialed International Biotech Leader Joins BoardAug 18, 2026Management or board changeASX
Appendix 4C and Quarterly Activities Report - June 2026Jul 30, 2026Quarterly reportASX
Photosoft Platform Expands to Eye Diseases Via PartnershipMay 18, 2026Operations updateASX
Appendix 4C and Quarterly Activities Report - March 2026Apr 30, 2026Quarterly reportASX
Skin Cancer Trial Moves to BCC With More Encouraging SignalsApr 21, 2026Operations updateASX
Appendix 4D and Half Year Financial ReportFeb 26, 2026Interim reportASX
Appendix 4C and Quarterly Activities Report - December 2025Jan 30, 2026Quarterly reportASX
Major Shareholders Lead Invion $1.3M Capital RaiseJan 30, 2026FinancingASX
Trading HaltJan 28, 2026Trading halt or suspensionASX
Pause in TradingJan 28, 2026Trading halt or suspensionASX
Hanlim & Korean Government Fund Pathway to Clinical TrialDec 22, 2025FinancingASX
Invion Secures Expanded Photosoft Global Exclusive LicenseDec 2, 2025Acquisition or disposalASX
Appendix 4C and Quarterly Activities Report - September 2025Oct 30, 2025Quarterly reportASX
Funded Collaboration Agreement with Protect Animal HealthOct 20, 2025Operations updateASX
Repayment of Lind Facility with Successful Capital RaiseOct 9, 2025FinancingASX
Response to ASX Aware LetterAug 27, 2025Explanation requestASX
Appendix 4E and Annual ReportAug 27, 2025Annual reportASX
Response to ASX Price QueryAug 20, 2025Explanation requestASX
Orphan Drug Designation Granted by U.S. FDA For Anal CancerAug 20, 2025Other filingsASX
Appendix 4C and Quarterly Activities Report - June 2025Jul 31, 2025Quarterly reportASX
Security Class Reinstatement to QuotationJul 17, 2025Trading halt or suspensionASX
Security Class Suspension from QuotationJul 10, 2025Trading halt or suspensionASX
Underwritten Loyalty Option Entitlement Offer ProspectusJun 23, 2025Offer documentASX
EQR Progresses Regional Tungsten Hub StrategyJun 13, 2025Other filingsASX
Loyalty Option Entitlement OfferJun 13, 2025FinancingASX
Encouraging SRC Findings on Ph I/II Skin Cancer TrialMay 28, 2025Operations updateASX
Dosing of 1st Six Patients in Phase I/II Skin Cancer TrialMay 1, 2025Operations updateASX
Appendix 4C and Quarterly Activities Report - March 2025Apr 30, 2025Quarterly reportASX
Share Purchase Agreement Termination and Tranche RepaymentMar 4, 2025Other filingsASX
Completion Of Placement to Accelerate Clinical ProgramsMar 4, 2025FinancingASX
Oesophageal Cancer Collaboration and Funding AgreementFeb 25, 2025Operations updateASX
Activities Report and Appendix 4CJan 30, 2025Quarterly reportASX
Invion Doses First Patient in Phase I/II Skin Cancer TrialDec 2, 2024Other filingsASX
Consolidation/Split - IVXOct 14, 2024Other filingsASX
Ph 2 Prostate Cancer Results Strong Safety and 40% ResponseSep 17, 2024Other filingsASX
Invion secures funding through an institutional placementJun 27, 2024FinancingASX
Agreement with Major South Korean Pharma Group HanlimMay 7, 2024Operations updateASX
INV043 With ICI Therapy Achieved 80% Tumour Control For ASCCMar 4, 2024Operations updateASX
Agreement with Dr.inB to develop Photosoft treatment for HPVFeb 22, 2024Operations updateASX
AGM PresentationNov 28, 2023Other filingsASX
Major Milestone towards Clinical TrialsNov 21, 2023Other filingsASX
Investor PresentationOct 23, 2023Other filingsASX
Photosoft Territory Expanded to South Korea for CancerSep 24, 2023Operations updateASX
Appendix 4E and Preliminary Financial ReportAug 30, 2023ResultsASX
Expansion of Territory Rights to USA, Canada and Hong KongFeb 7, 2023Other filingsASX
INV043 Effective Against Anal Cancer SCC In VitroSep 14, 2022Other filingsASX
Response to ASX Aware QuerySep 13, 2022Explanation requestASX
Photosoft Shows Activity Against Zika VirusSep 7, 2022Other filingsASX
INV043 SIGNIFICANTLY IMPROVED CHECKPOINT INHIBITOR THERAPYMay 29, 2022Other filingsASX
Supplementary ProspectusNov 25, 2021Offer documentASX
ProspectusNov 22, 2021Offer documentASX
Share Purchase Plan Offer Booklet & Application FormNov 21, 2021FinancingASX
Capital Raising and expansion of Photosoft TerritoryNov 16, 2021FinancingASX
Further Information on Proof of Concept Pilot StudyOct 28, 2021Other filingsASX
Complete Regression of TNBC Tumours and Protective ImmunityOct 27, 2021Other filingsASX
Capital Raising & co-development for Photosoft TechnologyJun 2, 2021FinancingASX
Initial Proof-of-Concept results show INV043 to be effectiveMay 24, 2021Other filingsASX
App 4D and Financial Report for half year to 31 Dec 2020Feb 24, 2021Other filingsASX
Business Update and Change to Board and ManagementJul 28, 2020Operations updateASX
Activities Report and Appendix 4C June 2020 QuarterJul 28, 2020Quarterly reportASX
Invion subsidiary signs Supply Agreement with Pavay BiotechJun 30, 2020Other filingsASX
Appendix 4C - March 2020 quarterApr 20, 2020Quarterly reportASX
App 4D and Financial Report for half year to 31 Dec 2019Feb 24, 2020Other filingsASX
Invion signs R&D Services Agreement with Pavay BiotechFeb 2, 2020Other filingsASX
Appendix 4C - December 2019 quarterJan 29, 2020Quarterly reportASX
Additional Information to Prior AnnouncementNov 28, 2019Other filingsASX
Pre-clinical research agreement with Peter MacCallum CCOct 30, 2019Other filingsASX
Appendix 4C - September 2019 quarterOct 28, 2019Quarterly reportASX
Appendix 4E and Financial Report for year ended 30 June 2019Aug 28, 2019ResultsASX
COO Craig Newton to transition to Invion CEOJul 21, 2019Other filingsASX
Appendix 4C - June quarterJul 12, 2019Quarterly reportASX
Animal studies show IVX-P02 potential in metastatic cancersMay 27, 2019Other filingsASX
Quarterly UpdateApr 17, 2019Other filingsASX
Appendix 4D and Financial Report for Half Year to 31 Dec 18Feb 26, 2019Interim reportASX
Response to ASX Appendix 4C QueryFeb 20, 2019Explanation requestASX
Invion completes spin-out of respiratory assetsFeb 11, 2019Other filingsASX
General Meeting - Results of MeetingJan 30, 2019Meeting outcomeASX
Appendix 4C - December quarterJan 28, 2019Quarterly reportASX
Appendix 4C - September 2018 quarterOct 28, 2018Quarterly reportASX
New Photosoft formulation increased effect in ovarian cancerSep 24, 2018Other filingsASX
Spin out of respiratory assets for development in ChinaSep 4, 2018Other filingsASX
Appendix 4E Annual Report and Full Year Statutory AccountsAug 28, 2018Annual reportASX
Appendix 4C - June 2018 quarterJul 27, 2018Quarterly reportASX
Photosoft efficiently destroys ovarian cancer cells in vitroJul 4, 2018Other filingsASX
Appendix 4C - March 2018 quarterApr 25, 2018Quarterly reportASX
Invion alliance with Hudson Institute of Medical ResearchMar 19, 2018Other filingsASX
Completion iof Rights IssueMar 13, 2018FinancingASX
Appendix 4D and Financial Report for half year to 31 Dec 17Feb 27, 2018Interim reportASX
Rights Issue Information BookletFeb 11, 2018FinancingASX
Appendix 4C - December 2017 QuarterJan 28, 2018Quarterly reportASX
Appointment of Non Executive Director and ChairmanNov 30, 2017Management or board changeASX
AGM - Withdrawal of Resolution prior to MeetingNov 29, 2017Other filingsASX
AGM Notice of Meeting And Proxy FormOct 29, 2017Meeting noticeASX
Appendix 4C - cashflow statement for the September quarterOct 27, 2017Quarterly reportASX
Appendix 4G - Key to governance disclosuresOct 26, 2017Other filingsASX
Strategic Transaction UpdateSep 5, 2017Other filingsASX
Appendix 4E and Full Year Statutory AccountsAug 31, 2017Annual reportASX
Appendix 4C - quarterlyJul 30, 2017Quarterly reportASX
Invion announces strategic allianceApr 18, 2017Other filingsASX
Appendix 4D and Financial Report for half year to 31 Dec 16Feb 27, 2017Interim reportASX
Appendix 4C December quarterJan 30, 2017Quarterly reportASX
Appendix 4C for the September quarterOct 30, 2016Quarterly reportASX
Receipt of R&T tax rebateSep 12, 2016Other filingsASX
App 4E, Annual and Financial Report FY2016Aug 30, 2016Other filingsASX
Response to ASX Appendix 4C queryAug 8, 2016Explanation requestASX
Phase 2 data presented to American Thoracic SocietyMay 20, 2016Other filingsASX
End of Phase 2 Meeting for INV102 (nadolol)Apr 3, 2016Other filingsASX
Invion announces no secondary capital raiseMar 30, 2016Other filingsASX
Smoking cessation patent allowance and Operational updateMar 10, 2016Other filingsASX
Appendix 4D and Half Year AccountsFeb 26, 2016Interim reportASX
Invion completes SPP and PlacementFeb 11, 2016FinancingASX
Smoking cessation trial results of ongoing data analysisFeb 10, 2016Other filingsASX